Promising cocktail of targeted drugs and chemo takes on mantle cell lymphoma
NCT ID NCT03710772
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a combination of targeted drugs (ibrutinib, rituximab, venetoclax) plus chemotherapy in 51 newly diagnosed young adults with mantle cell lymphoma. The goal is to see if this approach can achieve a complete response—meaning no signs of cancer—after treatment. The study is active but no longer recruiting, and researchers are closely monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ibrutinib, rituximab, venetoclax, and combination chemotherapy (cyclophosphamide, vincristine, doxorubicin, dexamethasone)
- What this could lead to
- If successful, this combination could become a more effective first-line treatment for young patients with mantle cell lymphoma, potentially leading to longer remission and better disease control.
- What could go wrong
- This is a small phase II trial (51 participants) with no control group, so results may not apply broadly. The aggressive chemotherapy carries significant side effects, and the long-term safety and efficacy are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A shot at safer CAR t: early brain protection for lymphoma patients?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can donor immune cells be engineered to fight blood cancer?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- Can a targeted drug boost standard chemo for a rare blood cancer?
- Smartwatches track hidden heart risk in blood cancer patients